Isocaloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) incorporates an extensive spectrum of histologic liver abnormalities, varying from simple triglyceride accumulation in hepatocytes non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH), and it is the most frequent chronic liver disease in the industrialized world. Beyond liver related complications such as cirrhosis and hepatocellular carcinoma, NAFLD is also an emerging risk factor for type 2 diabetes and cardiovascular disease. Currently, lifestyle intervention including strategies to reduce body weight and to increase regular physical activity represents the mainstay of NAFLD management. Total caloric intake plays a very important role in both the development and the treatment of NAFLD; however, apart from the caloric restriction alone, modifying the quality of the diet and modulating either the macro- or micronutrient composition can also markedly affect the clinical evolution of NAFLD, offering a more realistic and feasible treatment alternative. The aim of the present review is to summarize currently available evidence from randomized controlled trials on the effects of different nutrients including carbohydrates, lipids, protein and other dietary components, in isocaloric conditions, on NAFLD in people at high cardiometabolic risk. We also describe the plausible mechanisms by which different dietary components could modulate liver fat content.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 1×
“Despite the positive results of these meta-analyses, it is important to underline some limitations such as the variability in daily dosage of vitamin E, the length of treatment, and the small sample size of the studies, except for the PIVENS and the TONIC studies [151,152].”
ResultThe multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)
Buzzetti, E., Pinzani, M., & Tsochatzis, E. A. (2016) · Metabolism · doi:10.1016/j.metabol.2015.12.012 · Cited by 3,119
Del Rio, D., Rodriguez-Mateos, A., Spencer, J. P. E., Tognolini, M., Borges, G., & Crozier, A. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4581 · Cited by 2,601 · cited 7×
“Noteworthy, the excess of adiposity, in particular abdominal adiposity, and insulin resistance are the major contributors to the development of several cardiometabolic abnormalities strictly related to the increased risk of cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM).”
BackgroundInfluentialMeta-Analysis: High-Dosage Vitamin E Supplementation May Increase All-Cause Mortality
Miller, E. R., Pastor-Barriuso, R., Dalal, D., Riemersma, R. A., Appel, L. J., & Guallar, E. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-1-200501040-00110 · Cited by 2,577 · cited 1×
“Furthermore, some concerns must be underlined about the possible negative effects of high doses of vitamin E (>400 IU/day) on all-cause mortality [153].”
Background(2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.04.006 · Cited by 1,875
Dietary fibre in foods: A review
Dhingra, D., Michael, M., Rajput, H., & Patil, R. T. (2012) · Journal of Food Science and Technology · doi:10.1007/s13197-011-0365-5 · Cited by 1,456
Wong, V. W.-S., Vergniol, J., Wong, G. L.-H., Foucher, J., Chan, H. L.-Y., Le Bail, B., Choi, P. C.-L., Kowo, M., Chan, A. W.-H., Merrouche, W., et al. (2010) · Hepatology · doi:10.1002/hep.23312 · Cited by 1,322 · cited 1×
“Transient elastography is the instrumental imaging performed for the evaluation of liver fibrosis, but it has a high rate of false positive results [41].”
BackgroundNonalcoholic Fatty Liver Disease: Pathology and Pathogenesis
Tiniakos, D. G., Vos, M. B., & Brunt, E. M. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102132 · Cited by 870
Ryan, M. C., Itsiopoulos, C., Thodis, T., Ward, G., Trost, N., Hofferberth, S., O’Dea, K., Desmond, P. V., Johnson, N. A., & Wilson, A. M. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.02.012 · Cited by 778
The Role of Vitamin E in Human Health and Some Diseases
Rizvi, S., Raza, S. T., Ahmed, F., Ahmad, A., Abbas, S., & Mahdi, F. (2014) · Sultan Qaboos University Medical Journal · doi:10.18295/2075-0528.1566 · Cited by 624 · cited 1×
“Vitamin E plays a key role in many physiological functions: it is one of the most powerful antioxidant and acts as free radical scavenger; it is also involved in the regulation of platelet aggregation, protein kinase C activation, immune function, gene expression, and other metabolic processes [143].”
BackgroundMaersk, M., Belza, A., Stødkilde-Jørgensen, H., Ringgaard, S., Chabanova, E., Thomsen, H., Pedersen, S. B., Astrup, A., & Richelsen, B. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.022533 · Cited by 603 · cited 3×
“…weight maintenance) vs. Sucrose (8%, 18% or 30% of the calories required for weight maintenance) 10 = LIVER FAT (CT) n.a. n.a. n.a.42.1 years 27.2 kg/m2 Maersk et al., 2012 [102] Randomized parallel-group 47 M/F Regular cola (1 L/day) or Milk (1 L/day) or Diet cola (1 L/day) or Water (1 L/day)…”
BackgroundInfluentialBjermo, H., Iggman, D., Kullberg, J., Dahlman, I., Johansson, L., Persson, L., Berglund, J., Pulkki, K., Basu, S., Uusitupa, M., et al. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.030114 · Cited by 490 · cited 2×
“In a 10-week isocaloric randomized and controlled trial [64], participants were assigned either a PUFA diet or a saturated fat diet.”
MethodHigh-Dose Resveratrol Supplementation in Obese Men
Poulsen, M. M., Vestergaard, P. F., Clasen, B. F., Radko, Y., Christensen, L. P., Stødkilde-Jørgensen, H., Møller, N., Jessen, N., Pedersen, S. B., & Jørgensen, J. O. L. (2013) · Diabetes · doi:10.2337/db12-0975 · Cited by 455
Rosqvist, F., Iggman, D., Kullberg, J., Cedernaes, J., Johansson, H.-E., Larsson, A., Johansson, L., Ahlström, H., Arner, P., Dahlman, I., et al. (2014) · Diabetes · doi:10.2337/db13-1622 · Cited by 429 · cited 1×
“Along this line, controlled intervention studies demonstrated that increasing dietary SFA in isocaloric substitution of carbohydrates [48] or PUFA [49] increased hepatic and visceral fat accumulation in healthy subjects.”
BackgroundDietary fat content modifies liver fat in overweight nondiabetic subjects
Westerbacka, J., Lammi, K., Häkkinen, A.-M., Rissanen, A., Salminen, I., Aro, A., & Yki-Järvinen, H. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1983 · Cited by 379 · cited 1×
“Along this line, controlled intervention studies demonstrated that increasing dietary SFA in isocaloric substitution of carbohydrates [48] or PUFA [49] increased hepatic and visceral fat accumulation in healthy subjects.”
BackgroundAeberli, I., Gerber, P. A., Hochuli, M., Kohler, S., Haile, S. R., Gouni-Berthold, I., Berthold, H. K., Spinas, G. A., & Berneis, K. (2011) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.013540 · Cited by 372
Chen, S., Zhao, X., Ran, L., Wan, J., Wang, X., Qin, Y., Shu, F., Gao, Y., Yuan, L., Zhang, Q., et al. (2015) · Digestive and Liver Disease · doi:10.1016/j.dld.2014.11.015 · Cited by 319 · cited 3×
“[123] observed a significant reduction in serum ALT and AST, fibroblast growth factor-21 and CK-18 after three months of treatment with 600 mg/day of resveratrol versus placebo, while no significant differences in hepatic fat content was found.”
BackgroundChiu, S., Sievenpiper, J. L., de Souza, R. J., Cozma, A. I., Mirrahimi, A., Carleton, A. J., Ha, V, Di Buono, M., Jenkins, A. L., Leiter, L. A., et al. (2014) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2014.8 · Cited by 314 · cited 2×
“Briefly, the first meta-analysis reported that, in healthy subjects, using high doses of fructose in terms of 104–220 g/day in a hypercaloric diet increased both liver fat content and serum ALT levels, while it did not produce any effect in isocaloric conditions [108].”
BackgroundZelber‐Sagi, S., Salomone, F., & Mlynarsky, L. (2017) · Liver International · doi:10.1111/liv.13435 · Cited by 273 · cited 2×
“have comprehensively reviewed the evidence on this aspect [45].”
BackgroundAllard, J. P., Aghdassi, E., Mohammed, S., Raman, M., Avand, G., Arendt, B. M., Jalali, P., Kandasamy, T., Prayitno, N., Sherman, M., et al. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.09.009 · Cited by 247 · cited 1×
“Observational studies focusing on dietary habits of patients with NASH have suggested the possible negative influence of SFA, since their diets were richer in SFA than in other fatty acids compared to subjects with simple liver steatosis [46] or to the general population [47].”
BackgroundBozzetto, L., Prinster, A., Annuzzi, G., Costagliola, L., Mangione, A., Vitelli, A., Mazzarella, R., Longobardo, M., Mancini, M., Vigorito, C., et al. (2012) · Diabetes Care · doi:10.2337/dc12-0033 · Cited by 227 · cited 2×
“, 2012 [53] Randomized, controlled, parallel group 36 M/F, T2DM MUFA diet (MUFA 28% TE) vs.”
BackgroundSelf-citationArgo, C. K., Patrie, J. T., Lackner, C., Henry, T. D., de Lange, E. E., Weltman, A. L., Shah, N. L., Al-Osaimi, A. M., Pramoonjago, P., Jayakumar, S., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2014.08.036 · Cited by 224
Mediterranean Diet and Prevention of Chronic Diseases
Romagnolo, D. F., & Selmin, O. I. (2017) · Nutrition Today · doi:10.1097/nt.0000000000000228 · Cited by 187
Heebøll, S., Kreuzfeldt, M., Hamilton-Dutoit, S., Kjær Poulsen, M., Stødkilde-Jørgensen, H., Møller, H. J., Jessen, N., Thorsen, K., Kristina Hellberg, Y., Bønløkke Pedersen, S., et al. (2016) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2015.1107620 · Cited by 154 · cited 2×
“In two of these studies, resveratrol at the dose of 500 mg/day and 1500 mg/day, respectively, did not induce any change in the different liver outcomes evaluated (liver fat content by imaging, liver markers, histological changes) [131,132].”
BackgroundMisciagna, G., del Pilar Díaz, M., Caramia, D. V., Bonfiglio, C., Franco, I., Noviello, M. R., Chiloiro, M., Abbrescia, D. I., Mirizzi, A., Tanzi, M., et al. (2017) · The Journal of nutrition, health and aging · doi:10.1007/s12603-016-0809-8 · Cited by 134 · cited 3×
“24 = LIVER FAT (1H-MRS) AST = n.a. n.a.12.8 years ALT =32.6 kg/m2 Misciagna et al., 2016 [82] Randomized parallel-group, controlled 98 M/F LGI diet (CHO: 50%, fat: 30%, protein: 15–20”
BackgroundInfluentialBravo, S., Lowndes, J., Sinnett, S., Yu, Z., & Rippe, J. (2013) · Applied Physiology, Nutrition, and Metabolism · doi:10.1139/apnm-2012-0322 · Cited by 86 · cited 3×
“, 2013 [103] Randomized parallel-group 64 M/F HFCS (8%, 18% or 30% of the calories required for weight maintenance) vs.”
BackgroundInfluentialUtzschneider, K. M., Bayer-Carter, J. L., Arbuckle, M. D., Tidwell, J. M., Richards, T. L., & Craft, S. (2013) · British Journal of Nutrition · doi:10.1017/s0007114512002966 · Cited by 81 · cited 2×
“, 2012 [81] Randomized parallel, double-bind 35 M/F LSAT diet (23% fat, 7% saturated fat, GI < 55) vs.”
BackgroundRivellese, A. A., Giacco, R., Annuzzi, G., De Natale, C., Patti, L., Di Marino, L., Minerva, V., Costabile, G., Santangelo, C., Masella, R., et al. (2008) · Clinical Nutrition · doi:10.1016/j.clnu.2007.07.005 · Cited by 56 · cited 1×
“On the other hand, MUFA can promote fatty acid deposition in adipose tissue rather than in the liver, enhancing the clearance of circulating triglyceride rich lipoproteins by lipoprotein lipase [61].”
BackgroundSelf-citationMa, J., Karlsen, M. C., Chung, M., Jacques, P. F., Saltzman, E., Smith, C. E., Fox, C. S., & McKeown, N. M. (2016) · Nutrition Reviews · doi:10.1093/nutrit/nuv047 · Cited by 28
Cited by
Arroyave-Ospina, J. C., Wu, Z., Geng, Y., & Moshage, H. (2021) · Antioxidants · doi:10.3390/antiox10020174 · Cited by 527
Mediterranean diet nutrients to turn the tide against insulin resistance and related diseases
Mirabelli, M., Chiefari, E., Arcidiacono, B., Corigliano, D. M., Brunetti, F. S., Maggisano, V., Russo, D., Foti, D. P., & Brunetti, A. (2020) · Nutrients · doi:10.3390/nu12041066 · Cited by 272
Boland, M. L., Oró, D., Tølbøl, K. S., Thrane, S. T., Nielsen, J. C., Cohen, T. S., Tabor, D. E., Fernandes, F., Tovchigrechko, A., Veidal, S. S., et al. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i33.4904 · Cited by 129
Della Pepa, G., Russo, M., Vitale, M., Carli, F., Vetrani, C., Masulli, M., Riccardi, G., Vaccaro, O., Gastaldelli, A., Rivellese, A. A., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108984 · Cited by 84
Self-citationThe influence of probiotics on bile acids in diseases and aging
Sivamaruthi, B. S., Fern, L. A., Rashidah Pg Hj Ismail, D. S. N., & Chaiyasut, C. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110310 · Cited by 73
Metadata
- Authors
- Della Pepa, G., Vetrani, C., Lombardi, G., Bozzetto, L., Annuzzi, G., & Rivellese, A.
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2017-09-26
- Volume
- 9
- Issue
- 10
- Pages
- 1065
- ISSN
- 2072-6643 (ISSN-L)
- OpenAlex
- W2756664690
- Cited by
- 68
- References
- 31
- FWCI
- 5.56
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.